The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of tumor-informed minimal residual disease (MRD) with clinical outcomes for muscle invasive bladder cancer (MIBC): A multicenter retrospective real-world analysis.
 
Ajitha Kommalapati
No Relationships to Disclose
 
George Laliotis
Employment - Natera
Stock and Other Ownership Interests - Natera
 
Michael Glover
No Relationships to Disclose
 
Grayce Selig
No Relationships to Disclose
 
Revathi Kollipara
Employment - Fort Wayne Medical Oncology & Hematology (I); Phreesia (I)
Stock and Other Ownership Interests - Fort Wayne Medical Oncology & Hematology (I); Fort Wayne Orthopedics (I); Phreesia (I)
 
Tamara Mahmood
Employment - Natera
Stock and Other Ownership Interests - Natera
 
Sumit Shah
Employment - Natera
Stock and Other Ownership Interests - Natera
 
Christopher J. Hoimes
Honoraria - Seagen
Consulting or Advisory Role - 2bPrecise; Bristol-Myers Squibb; Eisai; Genentech/Roche; Merck Sharp & Dohme; Prometheus; Seagen
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Seagen
Research Funding - Alkermes (Inst); Astellas Pharma (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); Bristol Myers Squibb Foundation (Inst); crispr therapeutics (Inst); Dynavax Technologies (Inst); Janssen Oncology (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); NanoCarrier (Inst); Nektar (Inst); NeoImmuneTech (Inst); Novartis (Inst); Seagen (Inst)
(OPTIONAL) Uncompensated Relationships - 2bPrecise (Inst)
 
Tyler F. Stewart
Consulting or Advisory Role - Seattle Genetics/Astellas
Research Funding - GRAIL
 
Shruti Sharma
Employment - Natera
Stock and Other Ownership Interests - Natera
 
Meenakshi Malhotra
Employment - Natera
Stock and Other Ownership Interests - Natera
 
Natalia Pajak
Employment - Natera
Stock and Other Ownership Interests - Natera
 
Mark Calhoun
Employment - Natera
Stock and Other Ownership Interests - Natera
 
Adam ElNaggar
Employment - Natera
Leadership - Natera
Stock and Other Ownership Interests - Natera
Consulting or Advisory Role - EMD Serono; GlaxoSmithKline
 
Minetta C. Liu
Employment - Natera
Stock and Other Ownership Interests - Natera
Research Funding - Eisai (Inst); Exact Sciences (Inst); Genomic Health (Inst); GRAIL (Inst); Menarini Silicon Biosystems (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); Genomic Health; GRAIL; Menarini Silicon Biosystems; Merck; Natera; Pfizer
 
Arnab Basu
Honoraria - Cardinal Health; Eisai; Gilead Sciences; Natera
Consulting or Advisory Role - Bristol-Myers Squibb/Pfizer; EMD Serono; Seagen
Speakers' Bureau - Eisai
Research Funding - Astellas Pharma (Inst); AVEO (Inst); Bristol-Myers Squibb/Celgene (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Merck (Inst); Natera (Inst)
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; Basilea; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; Dragonfly Therapeutics; EMD Serono; Genentech; Gilead Sciences; GlaxoSmithKline; Incyte; Infinity Pharmaceuticals; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen; Silverback Therapeutics; Urogen pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Alan Tan
Stock and Other Ownership Interests - Adaptimmune; Aprea AB; Bluebird Bio; Editas Medicine; FATE Therapeutics; ImmunityBio; Iovance Biotherapeutics; MEI Pharma; natera
Honoraria - Bristol Myers Squibb Foundation; EMD Serono; Exelixis; Gilead Sciences; Merck; Myovant Sciences; natera
Consulting or Advisory Role - Exelixis; Foundation Medicine; Myovant Sciences
Speakers' Bureau - bristol myers squibb; EMD Serono; Exelixis; Gilead Sciences; Merck; natera